 The FDA has signed off and removed the clinical hold for a cryopreserved formulation of Gamida Cell Ltds NASDAQ: GMDA GDA-201, an off-the-shelf cell therapy candidate for follicular and diffuse large B cell lymphomas. Gamida Cell expects to initiate a Phase 12. 